Patents by Inventor Paul John Thornalley

Paul John Thornalley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hesperetin and trans-resveratrol compositions and methods thereof
    Patent number: 11135145
    Abstract: The invention relates to a composition, in particular to an oral anti-ageing composition for treating hair ageing. This invention is based on the observation that the combination of hesperetin, a flavanone, derivable from a natural rutinoside hesperetin 7-rutinoside (also known as hesperidin) in citrus, e.g., in Citrus aurantium L, Citrus sinensis, Zanthozylum gilletti, leaves of Agathosma serratifolia, and trans-resveratrol synergistically up-regulates NQO-1 in a gene expression assay. The combination also induces Glo1, decreases MG and MG-protein glycation, decreases insulin resistance, decreases fasting plasma glucose, induces modest weight loss, improves renal function, decreases vascular inflammation marker slCAM-1, improves arterial dilatation and decreases the risk of cardiovascular disease.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: October 5, 2021
    Inventors: Paul John Thornalley, Naila Rabbani, Mingzhan Xue
  • COMPOSITION FOR HAIR FOLLICLE GROWTH
    Publication number: 20180344603
    Abstract: The invention relates to a composition, in particular to an oral anti-ageing composition for treating hair ageing. This invention is based on the observation that the combination of hesperetin, a flavanone, derivable from a natural rutinoside hesperetin 7-rutinoside (also known as hesperidin) in citrus, e.g., in Citrus aurantium L, Citrus sinensis, Zanthozylum gilletti, leaves of Agathosma serratifolia, and trans-resveratrol synergistically up-regulates NQO-1 in a gene expression assay. The combination also induces Glo1, decreases MG and MG-protein glycation, decreases insulin resistance, decreases fasting plasma glucose, induces modest weight loss, improves renal function, decreases vascular inflammation marker slCAM-1, improves arterial dilatation and decreases the risk of cardiovascular disease.
    Type: Application
    Filed: November 7, 2016
    Publication date: December 6, 2018
    Applicant: CONOPCO, INC., d/b/a UNILEVER
    Inventors: Mark Ian Fowler, Gail Jenkins, David James Messenger, Naila Rabbani, Paul John Thornalley, Mingzhan Xue